{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054457","form_type":"8-K","ticker":null,"cik":"0001779020","company_name":"Danimer Scientific, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.052020+00:00","generated_at":"2026-06-02T19:31:13.877612+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Danimer Q1 revenue $10.2M, loss continues; FY2024 EBITDA guidance at lower end of $(22)-$(32)M","bullets":["Revenue $10.2M vs $11.9M YoY; PHA revenue up 64% ($3.2M), PLA down $4.3M from Ukraine conflict.","Adjusted EBITDA $(8.7)M vs $(8.9)M YoY; full-year guidance now 'closer to lower end' of $(22)-$(32)M.","Starbucks reapportioning Nodax straw business creates near-term Q2/Q3 headwinds; Danimer retains 100%.","First commercial order received for 20-million-pound cutlery award; $20M ABL facility closed April 19.","Proposed warrant dividend (1 per 3 shares) contingent on shareholder vote at July 9 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054457","json":"https://secwatch.observer/filing/0000950170-24-054457.json","markdown":"https://secwatch.observer/filing/0000950170-24-054457.md","text":"https://secwatch.observer/filing/0000950170-24-054457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1779020/000095017024054457/0000950170-24-054457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1779020/000095017024054457/dnmr-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:31:13.877612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"903048a3827b5f010dbd9eda653a3123d7b1fa5a","claim":"Danimer Scientific, Inc. reported first quarter ended March 31, 2024 results: revenue $10.2 million. Guidance reaffirmed.","evidence_excerpt":"new avenue to improve our balance sheet leverage, strengthen our capital structure and maximize stockholder value.” First Quarter 2024 Financial Highlights: • Revenues were $10.2 million in the first quarter of 2024 compared to revenue of $11.9 million in the first quarter of 2023. While PHA revenue increased by $3.2 million in the quarter as compared with the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000095017024054457/0000950170-24-054457-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$10.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}